Adverse transfusion reactions in onco-hematological patients at a specialty hospital
DOI:
https://doi.org/10.35381/s.v.v10i1.5023Keywords:
Blood transfusion, adverse effects, hematology, blood products, specialized hospitals, (Source: DeCS).Abstract
Objective: To report the most frequent adverse events in onco-hematological patients receiving blood product transfusions. Methods: This study was conducted in 2021 in the Hematology Department of a specialty hospital. Results: A total of 119 patients received blood product transfusions, and 19 experienced adverse events within the first 24 hours. The most frequent adverse reactions were fever, skin rash, hypotension, and headache. Conclusions: As these were polytransfused patients, most had received previous transfusions. Among all the patients who received apheresis and fresh frozen plasma, none experienced any adverse events during the first 24 hours post-transfusion.
Downloads
References
de Kruijff E, van Gammeren AJ, Porcelijn L, van Esser JWJ. Post-transfusion purpura in a woman with acute myeloid leukemia. Neth J Med. 2019;77:81-3. https://n9.cl/p3a9s
Fujiwara SI, Fujishima N, Kanamori H, Ito M, Sugimoto T, Saito S, et al. Released washed platelet concentrates are effective and safe in patients with a history of transfusion reactions. Transfus Apher Sci. 2018;57(6):746-51. https://doi.org/10.1016/j.transci.2018.09.001
Hasan M, Siddiqui IA, Qamar Z, Hayat A. An audit of transfusion reaction monitoring and reporting at a cancer hospital in Pakistan-a step towards haemovigilance. J Pak Med Assoc. 2021;71(2(B)):699-703. https://doi.org/10.47391/jpma.1185
Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev. 2019;37:100588. https://doi.org/10.1016/j.blre.2019.100588
Murphy MF. Hemovigilance drives improved transfusion safety. Transfusion. 2021;61(4):1333-5. https://doi.org/10.1111/trf.16322
Storch EK. Donor hemovigilance: a call to arms. Transfusion. 2020;60(6):1115-7. https://doi.org/10.1111/trf.15854
Whitaker BI, Belov A, Anderson SA. Progress in US hemovigilance: can we still learn from others? Transfusion. 2019;59(2):433-6. https://doi.org/10.1111/trf.15082
Ngo A, Masel D, Cahill C, Blumberg N, Refaai MA. Blood banking and transfusion medicine challenges during the COVID-19 pandemic. Clin Lab Med. 2020;40(4):587. https://doi.org/10.1016/j.cll.2020.08.013
Sostin N, Hendrickson JE. Pediatric hemovigilance and adverse transfusion reactions. Clin Lab Med. 2021;41(1):51-67. https://doi.org/10.1016/j.cll.2020.10.004
Wood EM, Ang AL, Bisht A, Bolton-Maggs PH, Bokhorst AG, Flesland O, et al. International haemovigilance: what have we learned and what do we need to do next? Transfus Med. 2019;29(4):221-30. https://doi.org/10.1111/tme.12582
Torres Quezada OC, Valarezo Carpio CK. Prevalencia de reacciones adversas postransfusionales en pacientes del hospital pediátrico Baca Ortiz en el período 2015-2020. 2022. https://repositorio.puce.edu.ec/handle/123456789/28814
Asadi F, Ramezanghorbani N. Proposing a Model for the National Hemovigilance Information System in Iran. J Med Life. 2020;13(2):211. https://doi.org/10.25122/jml-2019-0112
Yang L, Wu H, Jin X, Zheng P, Hu S, Xu X, et al. Study of cardiovascular disease prediction model based on random forest in eastern China. Sci Rep. 2020;10(1):5245. https://doi.org/10.1038/s41598-020-62133-5
Garraud O, Martinaud C. The plasma supply in France. Transfus Apher Sci. 2019;58(4):358-62. https://doi.org/10.1016/j.transci.2019.06.004v
Sobral PADS, Göttems LBD, Santana LA. Hemovigilance and patient safety: analysis of immediate transfusion reactions in elderly. Rev Bras Enferm. 2020;73:e20190735. https://doi.org/10.1590/0034-7167-2019-0735v
Garraud O, Cognasse F, Laradi S, Hamzeh-Cognasse H, Peyrard T, Tissot JD, et al. How to mitigate the risk of inducing transfusion-associated adverse reactions. Transfus Clin Biol. 2018;25(4):262-8. https://doi.org/10.1016/j.tracli.2018.07.006
Singh S, Chandel S, Sarma P, Reddy DH, Mishra A, Kumar S, et al. Biovigilance: A global perspective. Perspect Clin Res. 2019;10(4):155-62. https://doi.org/10.4103/picr.PICR_89_18
Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42(5):556-66. https://doi.org/10.1046/j.1537-2995.2002.00094.x
Huis in 't Veld EM, de Kort WL, Merz EM. Determinants of blood donation willingness in the European Union: a cross-country perspective on perceived transfusion safety, concerns, and incentives. Transfusion. 2019;59(4):1273-82. https://doi.org/10.1111/trf.15209
Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17(2):120-62. https://doi.org/10.1053/tmrv.2003.50009
Kato H, Uruma M, Okuyama Y, Fujita H, Handa M, Tomiyama Y, et al. Incidence of transfusion-related adverse reactions per patient reflects the potential risk of transfusion therapy in Japan. Am J Clin Pathol. 2013;140(2):219-24. https://doi.org/10.1309/AJCP6SBPOX0UWHEK
Timler D, Klepaczka J, Kasielska-Trojan A, Bogusiak K. Analysis of complications after blood components' transfusions. Pol J Surg. 2015;87(4):166-73. https://doi.org/10.1515/pjs-2015-0039
Tang CH, Huang YX, Lin YX, Yuan M. Analysis of related factors of adverse transfusion reactions. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(3):972-6. https://doi.org/10.19746/j.cnki.issn.1009-2137.2020.03.042
Negi G, Gaur DS, Kaur R. Blood transfusion safety: A study of adverse reactions at the blood bank of a tertiary care center. Adv Biomed Res. 2015;4(1):237. https://doi.org/10.4103/2277-9175.168604
Sharma DK, Datta S, Gupta A. Study of acute transfusion reactions in a teaching hospital of Sikkim: A hemovigilance initiative. Indian J Pharmacol. 2015;47(4):370-4. https://doi.org/10.4103/0253-7613.161257
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Veronica Narcisa Chiluisa-Suarez, Nairovys Gómez-Martínez, Ariel José Romero-Fernandez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
